Keith Marshall - Conatus Pharmaceuticals Insider

Conatus Pharmaceuticals Inc -- USA Stock  

USD 5.06  0.05  1%

CFO, Principal Financial Officer, COO, Executive Vice President

Mr. Keith W. Marshall, Ph.D. is Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President of the company. He was Chief Financial Officer and Head of Corporationrationrate Development since 2015 at Torque Therapeutics, where his responsibilities included finance, operations, human resources, corporate strategy and business development. He served as Managing Director and Advisor in Healthcare Investment Banking from 2012 to 2014 at GCA Savvian Advisors, where he provided strategic counsel to healthcare companies, and continued from 2014 to 2015 at TAG Healthcare Advisors under an alliance with GCA Savvian. Dr. Marshall was Managing Director from 2011 to 2012 at Sagent Advisors Managing Director, Cofounder, and Chief Financial Officer from 2008 to 2011 at Montgomery, Marshall Healthcare Partners Managing Director of Healthcare Investment Banking from 2003 to 2008 at Montgomery Co. and Associate in Healthcare Investment Banking from 2001 to 2003 at JPMorgan HQ with additional responsibilities at JPMorgan Partners
  President Since 2017  MBA    
858-376-2600  http://www.conatuspharma.com
Marshall previously worked as a Research Associate from 1990 to 1993 at ImmuLogic Pharmaceutical Corporationrationrationration, where he performed research under a collaboration with Merck around inhibition of MHC Class II molecules for autoimmune disease therapy. He holds an M.B.A. with concentrations in Finance, Strategy, and Entrepreneurship from the University of Chicago ? Booth School of Business; a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco; and an A.B. in Biology from Washington University in St. Louis.

Keith Marshall Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (23.97) % which means that it has lost $23.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (80.58) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 12.78 M in liabilities with Debt to Equity (D/E) ratio of 37.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals Inc has Current Ratio of 2.71 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Conatus Pharmaceuticals Inc (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 25 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Conatus Pharmaceuticals Inc to your portfolio

Top Management

Conatus Pharmaceuticals Leadership Team
Edward Smith, President, MBA
Michelle Vandertie, Executive
Dan Kisner, Director
James Scopa, Director
Steven Mento, CEO
Daniel Kisner, Director
Preston Klassen, Director
David Hale, Chairman
Harold Wart, Director, Ph.D
William LaRue, Director, MBA
Alfred Spada, Founder, Ph.D
Charles Cashion, President, MBA
Daniel Ripley, President, MBA
Keith Marshall, President, MBA
Louis Lacasse, Director, MBA
Shahzad Malik, Director
David Hagerty, President

Stock Performance

Conatus Pharmaceuticals Performance Indicators